when will tirzepatide be generic FDA confirms shortage is still over, gives compounders a grace period FDA to Evaluate Sandoz's Generic

Retatrutides published record is growing rapidly, anchored by Phase 2 obesity and type 2 diabetes results (PubMed IDs 37351564 and 37385275), with additional Phase 3 datasets expected as trials report out

Read our full take on what's at stake for patients and providers below

Assay: GSH/GSSG in mice tissues

Understanding how to protect your skin during sun exposure while on semaglutide therapy helps you maintain both your weight loss progress and skin health safely

discontinue immediately if suspected) Gallbladder disease and cholelithiasis (increased incidence with rapid weight loss) Acute kidney injury (usually secondary to severe dehydration from GI effects) Hypoglycemia (primarily when combined with insulin or sulfonylureas) Thyroid C-cell tumors (observed in rodent studies at clinically relevant exposures